🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the fight against superbug strains of the infection, according to scientists.

A Global Challenge

The sexually transmitted infection are on the rise worldwide, with figures suggesting in excess of 82 million infections per year. Especially elevated rates are observed in the African continent and nations within the WHO's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune step in the reality of rising global incidence, escalating drug resistance and the highly restricted therapeutic options at this time.”

Medical experts are increasingly worried about the increase in antibiotic-resistant strains. The World Health Organization has listed it as a "high-priority threat". Recent surveillance showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Gain Authorization

One new antibiotic, marketed under the name a brand name, was cleared by the US FDA in mid-December for use against gonorrhoea. This infection can lead to major issues, including infertility. Researchers anticipate that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, gained clearance in close succession. This drug, which is also used to treat UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin emerged from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This approval represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Testing Outcomes and Global Access

According to results detailed in a prominent scientific publication, the new drug cured over nine in ten of cases of the STI. This places it at an similar efficacy with the typical regimen, which uses an injection and a pill. The study enrolled over 900 participants from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the rights to make available and distribute the drug in many developing nations.

Doctors on the front lines have expressed hope. The availability of a single-dose, oral treatment such as this is hailed as a "revolutionary step" for managing the epidemic. This is considered essential to lessen the impact of the illness for patients and to stop the proliferation of untreatable gonorrhoea worldwide.